Increased Cerebrospinal Fluid Tau Levels in Logopenic Variant of Alzheimer's Disease

被引：9

作者：

Magnin, Eloi ^{[1
]}

Paquet, Claire ^{[2
]}

Formaglio, Maite ^{[3
]}

Croisile, Bernard ^{[3
]}

Chamard, Ludivine ^{[1
]}

Miguet-Alfonsi, Carole ^{[4
]}

Tio, Gregory ^{[1
]}

Dumurgier, Julien ^{[2
]}

Roullet-Solignac, Isabelle ^{[3
]}

Sauvee, Mathilde ^{[5
]}

Thomas-Anterion, Catherine ^{[6
]}

Vighetto, Alain ^{[3
]}

Hugon, Jacques ^{[2
]}

Vandel, Pierre ^{[1
]}

机构：

[1] CHU Besancon, Res Memory Ctr CMRR, F-25030 Besancon, France

[2] Univ Paris Diderot, AP HP, Res Memory Ctr CMRR, Paris, France

[3] CHU Lyon, Res Memory Ctr CMRR, Lyon, France

[4] CHU Besancon, Dept Biol, F-25030 Besancon, France

[5] CHU Nancy, Dept Neurol, Nancy, France

[6] CHU St Etienne, Reg Memory Ctr CMRR, St Priest En Jarez, France

来源：

JOURNAL OF ALZHEIMERS DISEASE | 2014年 / 39卷 / 03期

关键词：

Alzheimer's disease; cerebrospinal fluid markers; logopenic; mild cognitive impairment; primary progressive aphasia; PROGRESSIVE APHASIA; CSF BIOMARKERS; DECLINE;

D O I：

10.3233/JAD-131382

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Background: Patients with logopenic variant of primary progressive aphasia (lvPPA) display neuropathological differences from typical amnestic Alzheimer's disease (AD). Objective: The aim of the study was to compare cerebrospinal fluid (CSF) biomarker levels between patients with lvPPA due to AD (lvPPA-AD), non-logopenic forms of AD (nlAD), and amnestic mild cognitive impairment due to AD (aMCI-AD). Methods: CSF biomarker concentrations were assessed in 124 patients divided into three groups matched for age, level of education, center, and disease duration: lvPPA-AD (n = 30), nlAD (n = 67). and aMCI-AD (n = 27). Results: p-Tau181 levels were higher in the lvPPA-AD group than in the aMCI-AD group (p < 0.05). Total tau levels were higher in the lvPPA-AD group versus those in the nlAD (p < 0.05) and aMCI-AD (p < 0.001) groups. Conclusions: These results suggest a more pronounced involvement of a taupathy in lvPPA-AD compared to aMCI-AD and a more important neuronal death in lvPPA-AD than in nlAD or aMCI-AD.

引用

页码：611 / 616

页数：6

共 50 条

[1] Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease
Bekris, Lynn M.
Millard, Steve
Lutz, Franziska
Li, Gail
Galasko, Doug R.
Farlow, Martin R.
Quinn, Joseph F.
Kaye, Jeffrey A.
Leverenz, James B.
Tsuang, Debby W.
Yu, Chang-En
Peskind, Elaine R.
[J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2012, 159B (07) : 874 - 883
[2] Increased cerebrospinal fluid cAMP levels in Alzheimer's disease
Martínez, M
Fernández, E
Frank, A
Guaza, C
de la Fuente, M
Hernanz, A
[J]. BRAIN RESEARCH, 1999, 846 (02) : 265 - 267
[3] Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease
Green, AJE
Harvey, RJ
Thompson, EJ
Rossor, MN
[J]. NEUROSCIENCE LETTERS, 1999, 259 (02) : 133 - 135
[4] Cerebrospinal fluid levels of Aβ42 and tau:: potential markers of Alzheimer's disease
Galasko, D
[J]. JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1998, (53): : 209 - 221
[5] High Tau Levels in Cerebrospinal Fluid Predict Rapid Decline and Increased Dementia Mortality in Alzheimer's Disease
Gunnarsson, M. Degerman
Lannfelt, L.
Ingelsson, M.
Basun, H.
Kilander, L.
[J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2014, 37 (3-4) : 196 - 206
[6] Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease
Constantinescu, Radu
Romer, Megan
Zetterberg, Henrik
Rosengren, Lars
Kieburtz, Karl
[J]. PARKINSONISM & RELATED DISORDERS, 2011, 17 (09) : 714 - 715
[7] Tau oligomers in cerebrospinal fluid in Alzheimer's disease
Sengupta, Urmi
Portelius, Erik
Hansson, Oskar
Farmer, Kathleen
Castillo-Carranza, Diana
Woltjer, Randall
Zetterberg, Henrik
Galasko, Douglas
Blennow, Kaj
Kayed, Rakez
[J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (04): : 226 - 235
[8] DAYTIME SLEEPINESS IS ASSOCIATED WITH INCREASED CEREBROSPINAL FLUID TAU PROTEINS IN ALZHEIMER'S DISEASE
Okamoto, Cynthia
Sordo, Lorena
Neikrug, Ariel
Grill, Joshua
Head, Elizabeth
Benca, Ruth
Sultzer, David
Mander, Bryce
[J]. SLEEP, 2024, 47
[9] GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease
Cruchaga, Carlos
Kauwe, John S. K.
Harari, Oscar
Jin, Sheng Chih
Cai, Yefei
Karch, Celeste M.
Benitez, Bruno A.
Jeng, Amanda T.
Skorupa, Tara
Carrell, David
Bertelsen, Sarah
Bailey, Matthew
McKean, David
Shulman, Joshua M.
De Jager, Philip L.
Chibnik, Lori
Bennett, David A.
Arnold, Steve E.
Harold, Denise
Sims, Rebecca
Gerrish, Amy
Williams, Julie
Van Deerlin, Vivianna M.
Lee, Virginia M. -Y.
Shaw, Leslie M.
Trojanowski, John Q.
Haines, Jonathan L.
Mayeux, Richard
Pericak-Vance, Margaret A.
Farrer, Lindsay A.
Schellenberg, Gerard D.
Peskind, Elaine R.
Galasko, Douglas
Fagan, Anne M.
Holtzman, David M.
Morris, John C.
Goate, Alison M.
[J]. NEURON, 2013, 78 (02) : 256 - 268
[10] Elevated cerebrospinal fluid tau levels: Implications for the early diagnosis of Alzheimer's disease
Terajima, M
Arai, H
Itabashi, S
Higuchi, M
Zhu, CQ
Kosaka, Y
Nakagawa, T
Sasaki, H
[J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1996, 44 (08) : 1012 - 1013

← 1 2 3 4 5 →